NEW YORK – Single-cell proteomics firm IsoPlexis said today that it is partnering with researchers at the Department of Medicine at Columbia University to study the immune response in COVID-19 patients.
The Branford, Connecticut-based company said it plans to use its single-cell proteomics platform to identify drivers of durable and protective immune responses to the virus, with the ultimate goal of using that information to inform therapeutics development.
"We are looking forward to our partnership with Columbia University in the fight against COVID-19," IsoPlexis CEO Sean Mackay said in a statement. "This work will provide critical functional insights into the mechanisms of protective and durable immune response to COVID-19, especially with regards to the activity of T cells."
Financial and other terms of the agreement were not disclosed.